Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Rheumatology
•
Rheumatoid Arthritis
•
General Rheumatology
•
JAK Inhibitors
•
Hepatology & Liver Transplantation
•
Cirrhosis
Do you avoid JAK inhibitors in patients with a history of liver disease including NAFLD or cirrhosis?
Related Questions
Are there any immunosuppressive agents that have been shown to have utility in concurrent idiopathic anaphylaxis?
Would you prescribe a JAK inhibitor in patients with baseline transaminase elevation?
What is your approach to using topical JAK inhibitors in the management of cutaneous manifestations of rheumatic disease?
What is your approach to the evaluation of a patient with persistent costochondritis?
What is your approach to differentiating and managing DMARD-induced nodulosis (induced by methotrexate or leflunomide for example) from "de novo" RA nodules in seropositive RA patients?
Are there concerns with combining anti-IL5 biologics (mepolizumab or benralizumab) for severe asthma with other biologics for RA (e.g. TNFi)?
How do you approach immunosuppression in patients with a positive Interferon Gamma Release Assay and prior intravesicular BCG treatment for bladder cancer?
Can JAK inhibitors for established rheumatoid arthritis be continued when starting an immune checkpoint inhibitor?
How do you approach monitoring when using combination JAK inhibitors and methotrexate in RA?
How do you manage a patient with severe RA or SLE that worsens after stopping immunosuppressants due to having chronic foot ulceration?